Showing results (91-100 of 110) with videos related to
Sort By:
Pageof 11
European Journal of Haematology|July 28, 2023
Idelalisib (PI3Kδ inhibitor) therapy for patients with relapsed/refractory chronic lymphocytic leukemia: A Swedish nation-wide real-world report on consecutively identified patientsAgnes Mattsson, Sandra Eketorp Sylvan, Per Axelsson, et al.Cancer|January 5, 2023
Whole-body MRI surveillance in TP53 carriers is perceived as beneficial with no increase in cancer worry regardless of previous cancer: Data from the Swedish TP53 StudyMeis Omran, Hemming Johansson, Claudia Lundgren, et al.Acta Oto-Laryngologica|January 13, 2022
Mandibular resection in patients with head and neck cancer: acute and long-term complications after reconstructionMats Sjöström, Daniel Danielsson, Eva Munck-Wikland, et al.Breast Cancer Research and Treatment|December 1, 2017
Long-term safety and survival outcomes from the Scandinavian Breast Group 2004-1 randomized phase II trial of tailored dose-dense adjuvant chemotherapy for early breast cancerAlexios Matikas, Sara Margolin, Mats Hellström, et al.Leukemia & Lymphoma|February 15, 2014
Cladribine prolongs progression-free survival and time to second treatment compared to fludarabine and high-dose chlorambucil in chronic lymphocytic leukemiaStephen P Mulligan, Karin Karlsson, Mats Strömberg, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 17, 2024
Tailored Dose-Dense Versus Standard Adjuvant Chemotherapy for High-Risk Early Breast Cancer: End-of-Study Results of the Randomized PANTHER TrialAlexios Matikas, Volker Möbus, Richard Greil, et al.Cancers|February 25, 2022
Quality of Life in the First Year of Follow-Up in a Randomized Multicenter Trial Assessing the Role of Imaging after Radical Surgery of Stage IIB-C and III Cutaneous Melanoma (TRIM Study)Ylva Naeser, Hildur Helgadottir, Johan Hansson, et al.Cancer|December 19, 2019
Efficacy and safety of tailored and dose-dense adjuvant chemotherapy and trastuzumab for resected HER2-positive breast cancer: Results from the phase 3 PANTHER trialAntroula Papakonstantinou, Alexios Matikas, Nils Olof Bengtsson, et al.NPJ Breast Cancer|March 7, 2025
Machine learning-based spatial characterization of tumor-immune microenvironment in the EORTC 10994/BIG 1-00 early breast cancer trialIoannis Zerdes, Alexios Matikas, Artur Mezheyeuski, et al.International Journal of Cancer|November 18, 2014
MGMT promoter methylation is associated with temozolomide response and prolonged progression-free survival in disseminated cutaneous melanomaRainer Tuominen, Rosalyn Jewell, Joost J van den Oord, et al.Pageof 11